(19)
(11) EP 1 674 107 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
25.01.2017 Bulletin 2017/04

(45) Mention of the grant of the patent:
24.08.2016 Bulletin 2016/34

(21) Application number: 06006697.4

(22) Date of filing: 24.09.1999
(51) International Patent Classification (IPC): 
A61K 38/12(2006.01)
 A61P 31/04(2006.01)

(54)

Use of daptomycin

Verwendung von Daptomycin

Utilisation de daptomycin

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GR IE IT LI LU MC NL PT SE
Designated Extension States:
SI

(30) Priority: 25.09.1998 US 101828 P
24.03.1999 US 125750 P

(43) Date of publication of application:
28.06.2006 Bulletin 2006/26

(62) Application number of the earlier application in accordance with Art. 76 EPC:
99949913.0 / 1115417

(73) Proprietor: Cubist Pharmaceuticals LLC
6000 Lucerne 6 (CH)

(72) Inventors:
  • Oleson, Frederick B. Jr.
    Concord, MA01742 (US)
  • Tally, Francis P.
    Lincoln, MA 01733 (US)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)


(56) References cited: : 
EP-A- 0 386 951
WO-A-99/30728
 WO-A-98/22107
   
  • J.R. WOODWORTH ET AL.: "SINGLE-DOSE PHARMACOKINETICS AND ANTIBACTERIAL ACTIVITY OF DAPTOMYCIN, A NEW LIPOPEPTIDE ANTIBIOTIC, IN HEALTHY VOLUNTEERS.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 36, no. 2, February 1992 (1992-02), pages 318-325, XP000891776, BETHESDA, US
  • J.R. WOODWORTH ET AL.: "TOBRAMYCIN AND DAPTOMYCIN DISPOSITION WHEN CO-ADMINISTERED TO HEALTHY VOLUNTEERS", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 33, no. 3, March 1994 (1994-03), pages 655-659, XP000891828, LONDON, GB
  • E. BERNARD ET AL.: "PHARMACOKINETICS AND SUCTION BLISTER FLUID PENETRATION OF A SEMISYNTHETIC INJECTABLE STREPTOGRAMIN RP 59500 (RP 57669/RP 54476)", EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES,DE,WIESBADEN, vol. 13, no. 9, 1 September 1994 (1994-09-01), pages 768-771, XP002037989,
  • F.P. TALLY ET AL.: "DAPTOMYCIN: A NOVEL AGENT FOR GRAM-POSITIVE INFECTIONS.", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 8, no. 8, August 1999 (1999-08), pages 1223-1228, XP000891801, LONDON, GB
  • R.C. MOELLERING ET AL.: "THE EFFICACY AND SAFETY OF QUINUPRISTIN/DALFOPRISTIN FOR THE TREATMENT OF INFECTIONS CAUSED BY VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM.", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 44, no. 2, August 1999 (1999-08), pages 251-261, XP000891830, london, gb
  • KENNEDY S ET AL: "Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY SEP 1989 LNKD- PUBMED:2554799, vol. 33, no. 9, September 1989 (1989-09), pages 1522-1525, XP009159386, ISSN: 0066-4804
  • OLESON F B ET AL: "ONCE-DAILY DOSING DECREASES TOXICITY OF DAPTOMYCIN", TOXICOLOGICAL SCIENCES, ACADEMIC PRESS, vol. 48, 1 January 1999 (1999-01-01), page 322, XP009039198, ISSN: 1096-6080
  • RICHARD H. BALTZ: 'Lipopeptide antibiotics produced by Streptomyces roseosporus and Streptomyces fradiae' 01 January 1997, pages 415 - 435, XP055201803
  • N.N.: "Cubist starts pivotal trials with daptomycin", Scrip Newsletter, 10 March 1999 (1999-03-10), XP055201798, [retrieved on 2015-07-13]
  • N.N.: "Cubist pharmaceuticals initiates pivotal clinical trials for Daptomycin; novel antiinfective to treat serious life threatening infections.", , 1 March 1999 (1999-03-01), XP055201792, [retrieved on 2015-07-13]
 
Remarks:
This application was filed on 30 - 03 - 2006 as a divisional application to the application mentioned under INID code 62.
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).